BHCM
LXEO icon

Brevan Howard Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Brevan Howard Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,400
Closed -$122K – 2085
2025
Q3 		$122K Buy
+18,400
New +$89K ﹤0.01% 1844

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Brevan Howard Capital Management's LXEO Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Lexeo Therapeutics (LXEO) in Q4 2025, closing a stake of 18,400 shares — an estimated $122K sold.

Brevan Howard Capital Management first reported a position in LXEO in Q3 2025 and held it in 1 quarter. The position peaked at $122K in Q3 2025. 146 funds tracked by Wall St. Rank hold LXEO as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Lexeo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 18,400 Lexeo Therapeutics shares in Q4 2025, an estimated $122K.
  • Brevan Howard Capital Management first reported a position in Lexeo Therapeutics in Q3 2025 and held it in 1 quarter.
  • Brevan Howard Capital Management's Lexeo Therapeutics position peaked at $122K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.